Eisai introduces in-house developed thyroid cancer drug Lenvima in Japan
In Japan, Lenvima is the first molecular targeted treatment approved with an indication for unresectable thyroid cancer which covers differentiated thyroid cancer as well as medullary thyroid carcinoma
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.